COST-EFFECTIVENESS OF OFATUMUMAB COMPARED WITH OTHER DISEASE-MODIFYING THERAPIES FOR THE TREATMENT OF RELAPSING MULTIPLE SCLEROSIS IN GREECE

被引：0

作者：

Petropoulos, A. ^{[1
]}

Cooney, P. ^{[2
]}

Patidar, M. ^{[3
]}

Gudala, K. ^{[3
]}

Tiwari, S. ^{[4
]}

Brennan, R. ^{[2
]}

Kapsogeorgiou, K. ^{[1
]}

Cheilas, G. ^{[1
]}

Banhazi, J. ^{[5
]}

机构：

[1] Novartis Hellas SACI, Athens A1, Greece

[2] Novartis Ireland Ltd, Dublin, Ireland

[3] Novartis Healthcare Private Ltd, Hyderabad, India

[4] Novartis Healthcare Private Ltd, Hyderabad, Andhra Pradesh, India

[5] Novartis Pharma AG, Basel, BS, Switzerland

来源：

VALUE IN HEALTH | 2022年 / 25卷 / 12期

关键词：

D O I：

暂无

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

EE143

引用

页码：S80 / S81

页数：2

共 50 条

[11] Cost-effectiveness analyses of natalizumab (Tysabri®) compared with other disease-modifying therapies for people with highly active relapsing-remitting multiple sclerosis in the UK [J].

Gani, Ray ;

Giovannoni, Gavin ;

Bates, David ;

Kemball, Belinda ;

Hughes, Steve ;

Kerrigan, John .

PHARMACOECONOMICS, 2008, 26 (07) :617-627

[12] Cost-Effectiveness Analyses of Natalizumab (Tysabri®) Compared with Other Disease-Modifying Therapies for People with Highly Active Relapsing-Remitting Multiple Sclerosis in the UK [J].

Ray Gani ;

Gavin Giovannoni ;

David Bates ;

Belinda Kemball ;

Steve Hughes ;

John Kerrigan .

PharmacoEconomics, 2008, 26 :617-627

[13] Cost-Effectiveness of Multiple Sclerosis Disease-Modifying Therapies: A Systematic Review of the Literature [J].

Yamamoto, David ;

Campbell, Jonathan D. .

AUTOIMMUNE DISEASES, 2012, 2012

[14] Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies [J].

Simoens, Steven .

FRONTIERS IN NEUROLOGY, 2022, 13

[15] Cost-Effectiveness of Disease-Modifying Therapies in the Management of Multiple Sclerosis for the Medicare Population [J].

Tappenden, Paul ;

McCabe, Christopher ;

Chilcott, Jim ;

Simpson, Emma ;

Nixon, Richard ;

Madan, Jason ;

Fisk, John D. ;

Brown, Murray .

VALUE IN HEALTH, 2009, 12 (05) :657-665

[16] COST EFFECTIVENESS OF OFATUMUMAB IN COMPARISON WITH OTHER DISEASE MODIFYING THERAPIES AND BEST SUPPORTIVE CARE FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS IN CANADA [J].

Mouallif, S. ;

Thomas, K. ;

Adlard, N. E. ;

Cooney, P. ;

Blanchette, F. ;

Patel, B. P. ;

Baharnoori, M. ;

Bhan, V ;

Clift, F. ;

Grima, D. .

VALUE IN HEALTH, 2022, 25 (01) :S63-S63

[17] Cost effectiveness of Ofatumumab in Comparison with Other Disease Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada [J].

Mouallif, Soukaina ;

Thomas, Kim ;

Adlard, Nicholas ;

Cooney, Philip ;

Blanchette, Francois ;

Patel, Barkha ;

Baharnoori, Moogeh ;

Bhan, Virender ;

Clift, Fraser ;

Grima, Daniel .

NEUROLOGY, 2022, 98 (18)

[18] Effectiveness of disease-modifying therapies in relapsing multiple sclerosis in south china [J].

Tao, V. ;

Zhao, L. ;

Au, C. ;

Ng, A. ;

Mok, V. ;

Lau, A. .

MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) :531-532

[19] CLADRIBINE TABLETS (CT) VERSUS OTHER DISEASE-MODIFYING THERAPIES IN THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS (RRMS) - COST-EFFECTIVENESS ANALYSIS. [J].

Zieiba, P. ;

Pawlik, D. ;

Wieczorek, J. ;

Wojcik, R. ;

Kaczor, M. P. .

VALUE IN HEALTH, 2020, 23 :S632-S632

[20] Comparative effectiveness of ublituximab versus other disease-modifying therapies in patients with relapsing multiple sclerosis [J].

Smith, N. ;

Jeyakumar, S. ;

Miskin, H. ;

Mok, K. ;

Mehta, R. ;

Beckerman, R. .

MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) :579-580

← 1 2 3 4 5 →